DermDetect signs strategic partnership  Agreement with MetaOptima to provide affordable Full Body Imaging services.

As a global company, MetaOptima strives to equip medical professionals with intelligent solutions that fit the needs of their practice. To further this initiative, we are pleased to announce a partnership with DermDetect to support our mission of providing accessible skin imaging services.

DermDetect provides mobile and affordable skin cancer screening services by adopting an intelligent dermatology ecosystem to capture, analyze, and store images of the skin. Harnessing the power of mobility, DermDetect offers 1056 office locations in over 900 cities to ensure that everyone has access to the dermatology services they need in order to promote the early detection of skin cancer.

Benefits
Not only does this model streamline workflows for the receiving dermatologist or GP by drastically reducing administrative and imaging tasks, it also increases patient accessibility while expediting urgent cases. Rather than waiting for upwards of three months for an appointment, patients can have their skin imaged and receive feedback based on their needs and schedule while experiencing peace of mind and promoting the early detection of skin cancer.

DermDetect signs Clinical Service Agreement with OHSU to provide color-code for ASCS participants.

New clinical service agreement between OHSU and DermDetect will allow the researchers at OHSU to color-code the ASCS images using the PACS Workstation and DermCloud technology provided by DermDetect.  Academic Dermatologist log-in to the DermCloud from anywhere in the world using the secure encrypted PACS technology that brings DICOM to dermatology for the first time.

Colorado has the highest per-capita rate of skin cancer, thanks to sunshine and high elevation

The number of people who die of cancer has dropped nationwide in the last 25 years, but the decline in Colorado is even steeper, according to data released Monday.

The cancer death rate has declined 31 percent in Colorado, compared with 27 percent nationally. Related, Colorado is in the top five states with the lowest percentage of people diagnosed with cancer, a statistic doctors link to the state’s healthy lifestyle, lower-than-average obesity rates and lower smoking rates.

“A good reason that Colorado does pretty well is that it’s a pretty healthy place,” said Dr. Myles Cockburn, co-leader of the University of Colorado Cancer Center’s Cancer Prevention and Control Program, which released the Colorado cancer data.

However, Colorado — one of the sunniest states and also with the highest average elevation of any state — has the nation’s highest per-capita rate of skin cancer.

Cancer remains the second-leading cause of death for Americans, behind heart disease, and the leading cause of death for Coloradans. In Colorado, 50 percent of men and 40 percent of women will have cancer in their lifetime, according to Cathy Bradley, deputy director of the CU Cancer Center.

Lung cancer remains the deadliest cancer in Colorado and most states, but it is not the most prevalent cancer in this state. The most commonly diagnosed cancer for men is prostate, while the most common among women is breast cancer. Lung cancer is the second-most common cancer for both sexes. Melanoma, the worst kind of skin cancer, is the fifth-most diagnosed cancer for men in Colorado and the sixth for women.

.Read the article here…..

Nevus count tied to BCC risk

REPORTING FROM IID 2018 – Dematology News, presented by 
ORLANDO – The more nevi a person has, the greater the risk of basal cell carcinoma, according to a review of over 200,000 subjects in decades-long health professional cohorts. It’s well known that nevi increase the risk of melanoma, and the study confirmed that fact. The basal cell carcinoma finding, however, is novel. “The relationship between nevi and non-melanoma skin cancer has not [previously] been clearly demonstrated in large population cohorts,” said lead investigator Erin X. Wei, MD, a dermatologist at Brigham and Women’s Hospital, Boston. “Nevus count serves as a convenient maker to identify patients at risk for both melanoma and basal cell carcinoma. Providers should be aware of these increased risks in patients with any nevi on the extremity, particularly 15 or more,” she said at the International Investigative Dermatology meeting. Read the article here…..